FDA grants priority review to BMS/AZ lipodystrophy drug metreleptin
This article was originally published in Scrip
Bristol-Myers Squibb and AstraZeneca won a priority review from the US FDA for the firms' biologic license application (BLA) for metreleptin as a treatment for metabolic disorders associated with inherited or acquired lipodystrophy (LD), a rare disease that causes a loss of fat tissue, especially under the skin, resulting in a deficit of the hormone leptin.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.